02/21
Headlines

TG Therapeutics

Healthcare Decliners: Sorrento Therapeutics (NASDAQ:SRNE), Fibrocell Science (NYSEMKT:FCSC), TG Therapeutics (NASDAQ:TGTX), CombiMatrix (NASDAQ:CBMX)

Mark Doerr02 mins

Sorrento Therapeutics Inc (NASDAQ:SRNE) announced in a press release that the National Institutes of Health (NIH) has provided funding for the development of bispecific antibodies. Two small business grants from the NIH will allow Sorrento to use its antibody conjugation technology platform to develop antibodies for two of the NIH’s anti-bacterial immunotherapies. Sorrento’s pipeline also…

Read More

Biotech Decliners: Amicus Therapeutics, Inc. (NASDAQ:FOLD), Relypsa Inc (NASDAQ:RLYP), Receptos Inc (NASDAQ:RCPT), TG Therapeutics, Inc. (NASDAQ:TGTX), Chimerix Inc (NASDAQ:CMRX)

Jayne Crisman03 mins

On May 9, 2014, Amicus Therapeutics, Inc. (NASDAQ:FOLD) updated its Investor Presentation for the Migalastat Monotherapy Program (the “Presentation”). The Company’s Chief Financial Officer, William D. Baird III and the Company’s Chief Operating Officer, Bradley L. Campbell, will present some or all of this Presentation to various investors in the coming months. A copy of…

Read More

Biotech Bullish Stocks: ImmuCell Corporation (NASDAQ:ICCC), TG Therapeutics, Inc. (NASDAQ:TGTX), Relypsa Inc (NASDAQ:RLYP), OHR Pharmaceutical Inc (NASDAQ:OHRP)

Mark DeFrance02 mins

ImmuCell Corporation (NASDAQ:ICCC), a growing animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, today announced financial results for its first quarter ended March 31, 2014. For the first quarter ended March 31, 2014, ImmuCell Corporation (NASDAQ:ICCC) reported a product sales increase…

Read More
FB Nasdaq FB Facebook

Biotech Stocks Touching New Highs: Oncothyreon (NASDAQ:ONTY), IGI Laboratories (NYSEMKT:IG), TG Therapeutics (NASDAQ:TGTX), Receptos Inc. (NASDAQ:RCPT)

Colin Pettis02 mins

4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss its full year and fourth quarter 2013 financial results and provide a review of its pipeline of products in development. Oncothyreon Inc. (USA) (NASDAQ:ONTY) stock performance was 1.92% in last session and finished the day at $3.72. Traded volume was 1.16 million shares in the last…

Read More